LBRX LBRX Schizophrenia Programs — Direct Research And Development Expenses

Similar metrics at other companies

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

MPLTPreclinical Program — Research And Development Expense

$5.52M-9.2%

GERNResearch and clinical expenses — R&D

$13M-5.1%

TNGXDiscovery Direct Program Expenses-RD — Research And Development Expense

$1.87M-60.0%

AMLXOther Programs — Research And Development Expense Excluding Acquired In Process Cost

$7.98M+111%

ZYMEExpense for other preclinical and research programs — R&D

$7.26M+19.6%

Questions, answered.

What is LBRX's schizophrenia programs — direct research and development expenses?

LBRX (LBRX) reported schizophrenia programs — direct research and development expenses of $5.81M in Q1 2026.

What does schizophrenia programs — direct research and development expenses mean?

This metric represents the total direct costs incurred for research and development activities specifically allocated to the company's schizophrenia therapeutic pipeline. It captures expenditures related to clinical trials, preclinical studies, and regulatory filings for drug candidates targeting neuropsychiatric disorders. Tracking this expense provides insight into the company's capital commitment to its primary therapeutic focus and the progression of its clinical-stage assets.